These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21289518)

  • 1. Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β III-tubulin in thymic epithelial tumors.
    Kaira K; Serizawa M; Koh Y; Miura S; Kaira R; Abe M; Nakagawa K; Ohde Y; Okumura T; Naito T; Murakami H; Takahashi T; Kondo H; Nakajima T; Endo M; Yamamoto N
    J Thorac Oncol; 2011 Mar; 6(3):606-13. PubMed ID: 21289518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
    Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
    Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
    Zhao D; Zhang W; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):196-200. PubMed ID: 22780973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
    Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
    J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
    Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
    Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology].
    Huang J; Hu H; Xie Y; Tang Y; Liu W; Zhong M
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):582-9. PubMed ID: 23828702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of ERCC1, p53, and class III β-tubulin do not reveal chemoresistance in endometrial cancer: results from an immunohistochemical study.
    Vandenput I; Capoen A; Coenegrachts L; Verbist G; Moerman P; Vergote I; Amant F
    Int J Gynecol Cancer; 2011 Aug; 21(6):1071-7. PubMed ID: 21792013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer.
    Hwang JE; Hong JY; Kim K; Kim SH; Choi WY; Kim MJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Lee KH; Lee JH; Cho SH; Chung IJ
    BMC Cancer; 2013 Sep; 13():431. PubMed ID: 24053422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ¹⁸F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms?
    Kaira K; Endo M; Shukuya T; Kenmotsu H; Naito T; Ono A; Tsuya A; Nakamua Y; Takahashi T; Murakami H; Kondo H; Nakajima T; Yamamoto N
    Neoplasma; 2012; 59(3):257-63. PubMed ID: 22329847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.
    Vilmar A; Garcia-Foncillas J; Huarriz M; Santoni-Rugiu E; Sorensen JB
    Lung Cancer; 2012 Mar; 75(3):306-12. PubMed ID: 21996087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of ERCC1, RRM1, TUBB3 in correlation with apoptosis repressor ARC, DNA mismatch repair proteins and p53 in liver metastasis of colorectal cancer.
    Tóth C; Sükösd F; Valicsek E; Herpel E; Schirmacher P; Renner M; Mader C; Tiszlavicz L; Kriegsmann J
    Int J Mol Med; 2017 Nov; 40(5):1457-1465. PubMed ID: 28949378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of excision repair cross-complementation group 1 and class III β-tubulin in thymic carcinoma.
    Okuda K; Oda R; Suzuki A; Tatematsu T; Haneda H; Moriyama S; Yano M; Nakanishi R
    Oncol Lett; 2017 May; 13(5):3144-3150. PubMed ID: 28521419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis.
    Zhang Z; Dou X; Yang H; Jia L; Qin K; Gao X; Yang B; Zhang W; Qin C; Zhang F; Shan B
    Pathol Res Pract; 2020 Feb; 216(2):152794. PubMed ID: 31902551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
    Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
    J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.
    Wang TB; Zhang NL; Wang SH; Li HY; Chen SW; Zheng YG
    Genet Mol Res; 2014 May; 13(2):3704-10. PubMed ID: 24854656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer.
    Han Y; Wang XB; Xiao N; Liu ZD
    Asian Pac J Cancer Prev; 2013; 14(5):2987-90. PubMed ID: 23803067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
    Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors.
    Kaira K; Serizawa M; Koh Y; Miura S; Kaira R; Abe M; Nakagawa K; Ohde Y; Okumura T; Murakami H; Tsuya A; Nakamura Y; Naito T; Takahashi T; Kondo H; Nakajima T; Endo M; Yamamoto N
    Lung Cancer; 2011 Dec; 74(3):419-25. PubMed ID: 21550686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.